SG11201700789SA - Polymorphs of selinexor - Google Patents

Polymorphs of selinexor

Info

Publication number: SG11201700789SA
Authority: SG; Singapore
Prior art keywords: selinexor; polymorphs
Prior art date: 2014-08-15

Application number

SG11201700789SA

Inventor

Brian Clinton Austad

David G Roe

Original Assignee

Karyopharm Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-15

Filing date

2015-08-14

Publication date

2017-02-27

2015-08-14 Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc

2017-02-27 Publication of SG11201700789SA publication Critical patent/SG11201700789SA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

SG11201700789SA 2014-08-15 2015-08-14 Polymorphs of selinexor SG11201700789SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462038069P	2014-08-15	2014-08-15
PCT/US2015/045395 WO2016025904A1 (en)	2014-08-15	2015-08-14	Polymorphs of selinexor

Publications (1)

Publication Number	Publication Date
SG11201700789SA true SG11201700789SA (en)	2017-02-27

Family

ID=53969460

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201808624VA SG10201808624VA (en)	2014-08-15	2015-08-14	Polymorphs of selinexor
SG11201700789SA SG11201700789SA (en)	2014-08-15	2015-08-14	Polymorphs of selinexor

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10201808624VA SG10201808624VA (en)	2014-08-15	2015-08-14	Polymorphs of selinexor

Country Status (19)

Country	Link
US (5)	US10519139B2 (en)
EP (2)	EP4112615A1 (en)
JP (3)	JP6777626B2 (en)
KR (1)	KR102608259B1 (en)
CN (3)	CN111484483B (en)
AU (4)	AU2015301484B2 (en)
CA (1)	CA2957266A1 (en)
CO (1)	CO2017001884A2 (en)
DK (1)	DK3180331T3 (en)
EA (1)	EA201790384A1 (en)
ES (1)	ES2926377T3 (en)
IL (1)	IL250328B (en)
MA (1)	MA40254B1 (en)
MX (2)	MX2017002013A (en)
NZ (1)	NZ728850A (en)
SG (2)	SG10201808624VA (en)
UA (1)	UA123535C2 (en)
WO (1)	WO2016025904A1 (en)
ZA (1)	ZA201700880B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102022716B1 (en)	2011-07-29	2019-09-18	카리오팜 쎄라퓨틱스, 인코포레이티드	Hydrazide containing nuclear transport modulators and uses thereof
SI3404027T1 (en)	2012-05-09	2020-08-31	Biogen Ma Inc.	Nuclear transport modulators and uses thereof
WO2014144772A1 (en)	2013-03-15	2014-09-18	Karyopharm Therapeutics Inc.	Methods of promoting wound healing using crm1 inhibitors
DK3492455T3 (en)	2013-06-21	2023-08-14	Karyopharm Therapeutics Inc	1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND THEIR USE IN THE TREATMENT OF SPECIFIC FORMS OF CANCER
SG10201808624VA (en) *	2014-08-15	2018-11-29	Karyopharm Therapeutics Inc	Polymorphs of selinexor
EP3397633A1 (en)	2015-12-31	2018-11-07	Karyopharm Therapeutics, Inc.	Nuclear transport modulators and uses thereof
WO2017117535A1 (en)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
US11034675B2 (en) *	2016-01-08	2021-06-15	Dr. Reddy's Laboratories Limited	Solid forms of Selinexor and process for their preparation
US11602530B2 (en)	2016-11-28	2023-03-14	Biogen Ma Inc.	CRM1 inhibitors for treating epilepsy
WO2018129227A1 (en)	2017-01-05	2018-07-12	Watson Laboratories Inc.	Novel crystalline forms of selinexor and process for their preparation
CN106831731B (en) *	2017-01-17	2019-11-08	广州市闻皓生物科技有限公司	A kind of synthetic method of Selinexor bulk pharmaceutical chemicals
WO2019232724A1 (en) *	2018-06-06	2019-12-12	Xw Laboratories, Inc.	Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) *	2018-10-04	2020-04-09	Deva Holding Anonim Sirketi	Novel solid dispersions of selinexor
KR20210141936A (en)	2019-03-20	2021-11-23	존슨 맛쎄이 퍼블릭 리미티드 컴파니	Co-crystal form of Cellinexer
MA55808A (en)	2019-05-01	2022-03-09	Karyopharm Therapeutics Inc	METHOD FOR PREPARING XPO1 INHIBITORS AND INTERMEDIATES FOR USE IN PREPARING XPO1 INHIBITORS
EP3968987A4 (en) *	2019-05-16	2022-10-26	Mayo Foundation for Medical Education and Research	Methods and materials for treating cancer
EP3808742A1 (en)	2019-10-16	2021-04-21	Sandoz AG	Polymorph of selinexor
WO2022087218A1 (en)	2020-10-21	2022-04-28	Karyopharm Therapeutics Inc.	Crystalline form of selinexor
CN112679477B (en) *	2020-12-17	2021-10-26	佛山奕安赛医药科技有限公司	Preparation method of celecoxib and intermediate thereof
WO2023122014A1 (en) *	2021-12-20	2023-06-29	Raytheon Technologies Corporation	Particle enhancement of ceramic matrix composites, method of manufacture thereof and articles comprising the same
CN116675677B (en) *	2023-08-02	2023-09-26	中国林业科学研究院林产化学工业研究所	C8 urushiol derivative and preparation method and application thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1017398A (en)	1911-01-16	1912-02-13	John E Folsom	Telegraph-key.
CS229934B2 (en)	1981-07-07	1984-07-16	Pfizer	Production method subst.indolylacryte acid derivative
KR840000529A (en)	1981-07-07	1984-02-25	콘스탄틴 루이스 클레멘트	Method for preparing indole derivative
US4778796A (en)	1985-07-19	1988-10-18	Dainippon Pharmaceutical Co., Ltd.	ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en)	1990-02-23	1995-01-24	Takeda Chemical Industries Ltd	4,5,6,7- Tetrahydrothiazolo (5,4-b) pyridine and 5,6-dihydro-4h pyrrolo (3,2-d) thiazolo compounds, their production and pharmaceutical compositions containing them
JP3111321B2 (en)	1990-02-23	2000-11-20	武田薬品工業株式会社	Condensed thiazole compound
US5541213A (en)	1993-06-24	1996-07-30	Eisai Co., Ltd.	Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en)	1994-05-05	1995-11-21	Minnesota Mining And Manufacturing Company	Mist suppressant for solvent extraction metal electrowinning
CN1088062C (en)	1994-11-23	2002-07-24	纽罗根公司	Certain 4 -aminomethyl -2 -substituted imidazole derivatives and 2 -aminomethyl -4 -substituted imidazole derivatives, new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en)	1995-06-07	2003-01-23	Neurogen Corporation, Corporation Of The State Of Delaware	Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997015567A1 (en)	1995-10-20	1997-05-01	Dr. Karl Thomae Gmbh	5-membered heterocycles, pharmaceutical agents containing said compounds and the use thereof and methods of producing them
DE69736775T2 (en)	1996-04-04	2007-08-23	Shionogi & Co., Ltd.	CEPHEM COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
CN1227229C (en)	1996-04-25	2005-11-16	日产化学工业株式会社	Ethylene derivatives and pest controlling agents
JP4054992B2 (en)	1996-04-25	2008-03-05	日産化学工業株式会社	Ethylene derivatives and pest control agents
DE19624659A1 (en)	1996-06-20	1998-01-08	Klinge Co Chem Pharm Fab	New pyridylalkene and pyridylalkanoic acid amides
US5994398A (en)	1996-12-11	1999-11-30	Elan Pharmaceuticals, Inc.	Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (en)	1997-12-19	2010-02-17	武田薬品工業株式会社	Anilide derivatives, their production and use
AU2960599A (en)	1998-03-30	1999-10-18	Akira Karasawa	Quinazoline derivatives
CO5271680A1 (en)	2000-02-21	2003-04-30	Smithkline Beecham Corp	COMPOUNDS
EP1335898B1 (en)	2000-09-29	2005-11-23	TopoTarget UK Limited	Carbamic acid compounds comprising an amide linkage as hdac inhibitors
MXPA04002397A (en)	2001-09-14	2004-12-02	Methylgene Inc	Inhibitors of histone deacetylase.
WO2004037248A2 (en)	2002-10-24	2004-05-06	Carex Sa	Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (en)	2002-10-31	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New amide compounds having MCH antagonist activity and medicaments containing these compounds
RU2337682C2 (en)	2002-11-01	2008-11-10	Такеда Фармасьютикал Компани Лимитед	Agent for prophylaxis and treatment of neuropathy
JP4145230B2 (en)	2002-11-01	2008-09-03	武田薬品工業株式会社	Preventive and therapeutic agents for neurological disorders
ATE552253T1 (en)	2002-11-08	2012-04-15	Novartis Int Pharm Ltd	3-SUBSTITUTED-6-ARYL-PYRIDINE DERIVATIVES AS LIGANDS FOR C5A RECEPTORS
EP1599447A1 (en)	2003-02-28	2005-11-30	Galderma Research & Development, S.N.C.	Ligands that modulate lxr-type receptors
WO2005115990A1 (en)	2004-05-26	2005-12-08	Eisai R & D Management Co., Ltd.	Cinnamide compound
EP1780210A4 (en)	2004-08-11	2009-06-10	Kyorin Seiyaku Kk	Novel cyclic aminobenzoic acid derivative
WO2006019020A1 (en)	2004-08-16	2006-02-23	Sankyo Company, Limited	Substituted ureas
JPWO2006088246A1 (en)	2005-02-18	2008-07-10	武田薬品工業株式会社	GPR34 receptor function regulator
KR101439557B1 (en) *	2005-11-15	2014-09-11	오츠카 세이야쿠 가부시키가이샤	Oxazole compound and pharmaceutical composition
JP2007210929A (en)	2006-02-09	2007-08-23	Sankyo Co Ltd	Medicine containing urea compound
EA016464B1 (en)	2006-03-09	2012-05-30	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Polycyclic arylimidazole derivative
EP2007720B1 (en)	2006-04-07	2013-12-25	MethylGene Inc.	Benzamide derivatives as inhibitors of histone deacetylase
PL2014652T3 (en)	2006-04-18	2015-02-27	Nippon Chemiphar Co	Activating agent for peroxisome proliferator activated receptor
WO2007147336A1 (en)	2006-06-13	2007-12-27	Shanghai Institue Of Materia Medica, Chinese Academy Of Sciences	Heterocyclic non-nucleoside compounds, their peparation, pharmaceutical composition and their use as antiviral agents
AR063211A1 (en)	2006-07-27	2009-01-14	Amorepacific Corp	DERIVATIVES OF 3- (PIRIDIN-3-IL) ACRILAMIDE AND 3- (PIRIDIN-3-IL) PROPIONAMIDE, A METHOD FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF ASSOCIATED DISEASES WITH THE VANILOID RECEIVER.
KR101404360B1 (en)	2006-09-05	2014-06-09	교와 핫꼬 기린 가부시키가이샤	Imidazole Derivative
EP1939180A1 (en)	2006-12-20	2008-07-02	sanofi-aventis	Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en)	2006-12-20	2008-07-09	sanofi-aventis	Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US7795457B2 (en)	2007-02-26	2010-09-14	Kosan Biosciences Incorporated	Carbamate compounds
EP2003118A1 (en)	2007-06-13	2008-12-17	Bayer Schering Pharma Aktiengesellschaft	Cinnamic acid derivatives as modulators of EP2 receptors
EP2323737A2 (en)	2008-08-08	2011-05-25	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
MX2012000434A (en)	2009-07-09	2012-04-11	Crescendo Therapeutics Llc	Method of wound healing and scar modulation.
WO2011069039A1 (en)	2009-12-04	2011-06-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hydrazone and diacyl hydrazine compounds and methods of use
EP2542089B1 (en)	2010-03-05	2017-01-18	Karyopharm Therapeutics, Inc.	Nuclear transport modulators and uses thereof
EP2665362B1 (en)	2011-01-17	2016-03-30	Karyopharm Therapeutics, Inc.	Olefin containing nuclear transport modulators and uses thereof
BR112014001933A2 (en)	2011-07-29	2017-02-21	Karyopharm Therapeutics Inc	nuclear transport modulators and their uses
KR102022716B1 (en)	2011-07-29	2019-09-18	카리오팜 쎄라퓨틱스, 인코포레이티드	Hydrazide containing nuclear transport modulators and uses thereof
WO2013020024A2 (en)	2011-08-03	2013-02-07	Karyopharm Therapeutics, Inc.	Maleimide compounds and methods of treatment
SI3404027T1 (en)	2012-05-09	2020-08-31	Biogen Ma Inc.	Nuclear transport modulators and uses thereof
WO2014152263A1 (en)	2013-03-15	2014-09-25	Karyopharm Therapeutics Inc.	Exo olefin-containing nuclear transport modulators and uses thereof
WO2014144772A1 (en)	2013-03-15	2014-09-18	Karyopharm Therapeutics Inc.	Methods of promoting wound healing using crm1 inhibitors
DK3492455T3 (en)	2013-06-21	2023-08-14	Karyopharm Therapeutics Inc	1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND THEIR USE IN THE TREATMENT OF SPECIFIC FORMS OF CANCER
WO2014205393A1 (en)	2013-06-21	2014-12-24	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
WO2015073908A1 (en) *	2013-11-15	2015-05-21	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Method for selecting cancer treatment regimen
CN105294682B (en) *	2014-07-26	2017-07-07	广东东阳光药业有限公司	Compound of CDK type small molecular inhibitors and application thereof
SG10201808624VA (en)	2014-08-15	2018-11-29	Karyopharm Therapeutics Inc	Polymorphs of selinexor
WO2017117535A1 (en)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
EP3397633A1 (en)	2015-12-31	2018-11-07	Karyopharm Therapeutics, Inc.	Nuclear transport modulators and uses thereof
US11034675B2 (en) *	2016-01-08	2021-06-15	Dr. Reddy's Laboratories Limited	Solid forms of Selinexor and process for their preparation
JP6765198B2 (en)	2016-03-10	2020-10-07	パナソニック株式会社	Latent heat storage material and heat storage system using it
US11602530B2 (en)	2016-11-28	2023-03-14	Biogen Ma Inc.	CRM1 inhibitors for treating epilepsy
WO2018129227A1 (en) *	2017-01-05	2018-07-12	Watson Laboratories Inc.	Novel crystalline forms of selinexor and process for their preparation

2015
- 2015-08-14 SG SG10201808624VA patent/SG10201808624VA/en unknown
- 2015-08-14 WO PCT/US2015/045395 patent/WO2016025904A1/en active Application Filing
- 2015-08-14 CN CN202010093491.4A patent/CN111484483B/en active Active
- 2015-08-14 US US15/503,319 patent/US10519139B2/en active Active
- 2015-08-14 MX MX2017002013A patent/MX2017002013A/en unknown
- 2015-08-14 MA MA40254A patent/MA40254B1/en unknown
- 2015-08-14 JP JP2017508087A patent/JP6777626B2/en active Active
- 2015-08-14 AU AU2015301484A patent/AU2015301484B2/en active Active
- 2015-08-14 ES ES15754099T patent/ES2926377T3/en active Active
- 2015-08-14 DK DK15754099.8T patent/DK3180331T3/en active
- 2015-08-14 EP EP22176543.1A patent/EP4112615A1/en active Pending
- 2015-08-14 EA EA201790384A patent/EA201790384A1/en unknown
- 2015-08-14 SG SG11201700789SA patent/SG11201700789SA/en unknown
- 2015-08-14 NZ NZ728850A patent/NZ728850A/en unknown
- 2015-08-14 UA UAA201702169A patent/UA123535C2/en unknown
- 2015-08-14 CN CN202010093239.3A patent/CN111481553B/en active Active
- 2015-08-14 CN CN201580056017.1A patent/CN107072992B/en active Active
- 2015-08-14 KR KR1020177006680A patent/KR102608259B1/en active IP Right Grant
- 2015-08-14 CA CA2957266A patent/CA2957266A1/en active Pending
- 2015-08-14 EP EP15754099.8A patent/EP3180331B1/en active Active
2017
- 2017-01-29 IL IL250328A patent/IL250328B/en unknown
- 2017-02-03 ZA ZA2017/00880A patent/ZA201700880B/en unknown
- 2017-02-14 MX MX2021014128A patent/MX2021014128A/en unknown
- 2017-02-24 CO CONC2017/0001884A patent/CO2017001884A2/en unknown
2019
- 2019-11-11 US US16/679,630 patent/US11078190B2/en active Active
2020
- 2020-05-19 AU AU2020203246A patent/AU2020203246B2/en active Active
- 2020-05-29 JP JP2020093874A patent/JP7218323B2/en active Active
2021
- 2021-07-01 US US17/365,656 patent/US11807629B2/en active Active
- 2021-12-14 AU AU2021286266A patent/AU2021286266B2/en active Active
2023
- 2023-01-25 JP JP2023009361A patent/JP2023052622A/en active Pending
- 2023-04-05 US US18/131,273 patent/US11753401B2/en active Active
- 2023-04-07 US US18/132,241 patent/US11746102B2/en active Active
2024
- 2024-04-30 AU AU2024202835A patent/AU2024202835A1/en active Pending

Also Published As

Publication number	Publication date
US20180215733A1 (en)	2018-08-02
EP3180331A1 (en)	2017-06-21
AU2020203246B2 (en)	2021-09-16
AU2024202835A1 (en)	2024-05-23
US10519139B2 (en)	2019-12-31
AU2021286266A1 (en)	2022-01-06
US11078190B2 (en)	2021-08-03
MA40254B1 (en)	2022-09-30
JP2020143144A (en)	2020-09-10
WO2016025904A1 (en)	2016-02-18
US20200283419A1 (en)	2020-09-10
SG10201808624VA (en)	2018-11-29
ES2926377T3 (en)	2022-10-25
AU2015301484A1 (en)	2017-03-02
UA123535C2 (en)	2021-04-21
JP6777626B2 (en)	2020-10-28
EP3180331B1 (en)	2022-06-08
JP7218323B2 (en)	2023-02-06
CN107072992B (en)	2020-03-10
KR20170043561A (en)	2017-04-21
JP2017527549A (en)	2017-09-21
CN111484483B (en)	2023-05-26
US20230242517A1 (en)	2023-08-03
JP2023052622A (en)	2023-04-11
MX2017002013A (en)	2017-05-12
US20230242516A1 (en)	2023-08-03
US11746102B2 (en)	2023-09-05
NZ728850A (en)	2024-03-22
CA2957266A1 (en)	2016-02-18
MX2021014128A (en)	2022-01-04
MA40254A (en)	2021-05-19
IL250328B (en)	2022-05-01
EP4112615A1 (en)	2023-01-04
CN111484483A (en)	2020-08-04
US20220135545A1 (en)	2022-05-05
US11807629B2 (en)	2023-11-07
CN111481553A (en)	2020-08-04
CO2017001884A2 (en)	2017-07-19
KR102608259B1 (en)	2023-11-29
AU2020203246A1 (en)	2020-06-04
US11753401B2 (en)	2023-09-12
IL250328A0 (en)	2017-03-30
EA201790384A1 (en)	2017-08-31
DK3180331T3 (en)	2022-09-12
CN107072992A (en)	2017-08-18
ZA201700880B (en)	2020-01-29
AU2021286266B2 (en)	2024-02-01
CN111481553B (en)	2023-09-01
AU2015301484B2 (en)	2020-02-20

Publication	Publication Date	Title
ZA201700880B (en)	2020-01-29	Polymorphs of selinexor
IL273230A (en)	2020-04-30	Synthesis of polycyclic-carbamoylpyridone compounds
SI3154526T1 (en)	2019-08-30	Solid state forms of sofosbuvir
HU4602U (en)	2016-04-28	Set of saggar assembly
IL246979A0 (en)	2016-09-29	Solid state forms of sofosbuvir
ZA201706282B (en)	2019-01-30	Solid forms of menaquinols
PL3113773T3 (en)	2020-05-18	Crystalline forms of grapiprant
IL265180B (en)	2022-01-01	New polymorphs and new solid states of tiacumicin b
ZA201608686B (en)	2020-08-26	Interseparation of metals
HU4603U (en)	2016-04-28	Set of saggar assembly
IL249130B (en)	2018-12-31	Preparation of piperidine-4-carbothioamide
GB2544217B (en)	2020-03-25	Chlorination of sucrose-6-esters
GB201403438D0 (en)	2014-04-16	Polymorphs
SI3253769T1 (en)	2019-05-31	Novel polymorphs
TWM489811U (en)	2014-11-11	Structural improvement of tube
IL249332A0 (en)	2017-02-28	Solid state forms of sofosbuvir
PL3137475T3 (en)	2019-01-31	Purification of epidaunorubicin
GB201416951D0 (en)	2014-11-12	Method of synthesis
GB201414267D0 (en)	2014-09-24	Chlorination of sucrose-6-esters
GB201404705D0 (en)	2014-04-30	Theory of Conceptual art